Acquired resistance to poly (ADP-ribose) polymerase inhibitor olaparib in BRCA2-associated prostate cancer resulting from biallelic BRCA2 reversion mutations restores both germline and somatic loss-of-function mutations

Benedito A. Carneiro*, Katharine Ann Collier, Rebecca J. Nagy, Sahithi Pamarthy, Vinay Sagar, Stephen Fairclough, Justin Odegaard, Richard B. Lanman, Ricardo Costa, Timothy Taxter, Timothy M. Kuzel, Alice Fan, Young Kwang Chae, Massimo Cristofanilli, Maha H. Hussain, Sarki A. Abdulkadir, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalArticle

16 Scopus citations
Original languageEnglish (US)
JournalJCO Precision Oncology
Volume2
DOIs
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this